Evidence map›Paper›PMID 42572417›Full record

Trial reportAnnals of medicine2026

Comparison of Keverprazan-based versus esomeprazole-based dual therapy for initial treatment of

Zhaoli Ma, Xi Gou, Hongjuan Ma, Hong Lu, Min Liu, Hao Yuan, Qiang Li, Jun Wang, Huizhen Yang, Yuling Wang and 8 more

Abstract readMulticenter StudyRandomized Controlled TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Zhaoli MaThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu Province, China.ORCID 0009-0000-9517-0800
Xi GouDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, Gansu Province, China.
Hongjuan MaDepartment of Gastroenterology, Dingxi People's Hospital, Dingxi, Gansu Province, China.
Hong LuThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu Province, China.
Min LiuThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu Province, China.
Hao YuanThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu Province, China.
Qiang LiThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu Province, China.
Jun WangDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, Gansu Province, China.
Huizhen YangDepartment of Gastroenterology, Tanchang People's Hospital, Longnan, Gansu Province, China.
Yuling WangDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, Gansu Province, China.
Zhaofeng ChenThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu Province, China.
Xiaochuang ShuDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, Gansu Province, China.
Yue ZhaoThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu Province, China.
Chen LiThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu Province, China.
Wenjin LiThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu Province, China.
Ya ZhengThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu Province, China.
Rui JiThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu Province, China.
Qian RenThe First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKeverprazan offers a new perspective for

methodsThis was a prospective, open-label, multicenter, randomized controlled trial in adult patients with treatment-naive

resultsA total of 264 patients were enrolled in the study. In the intention-to-treat (ITT) analysis, the eradication rates for the 14-day KA group and the 14-day EA group were 87.9% and 80.3%, respectively (

conclusionFor treatment-naive

Indexed as

AmoxicillinAnti-Bacterial AgentsEsomeprazoleHelicobacter InfectionsHelicobacter pyloriProton Pump InhibitorsAdultAgedDrug Therapy, CombinationFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeAmoxicillinAnti-Bacterial AgentsEsomeprazoleProton Pump Inhibitorsdual therapyeradication rateesomeprazoleHelicobacter pyloriKeverprazanpotassium-competitive acid blocker

Identifiers

PMID42572417
PMCPMC13537056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.